Searchable abstracts of presentations at key conferences in endocrinology

ea0016p523 | Obesity | ECE2008

Obesity in GDM: a registry of GDM in Portugal

Ruas Luisa , Paiva Sandra , Rocha Tiago , Dores Jorge , Carvalheiro Manuela

Introduction: A retrospective study of the year 2003, of 1314 women with GDM, from 24 public health Centres in Portugal, was performed.Patients and methods: Women were divided into two groups according to their pre-pregnancy BMI: group Go – BMI ≥30 kg/m2 and group Gno BMI <30 kg/m2. The mean age of these women was 32.9±5 years (18–45), the A1c was <6% in both groups. The influence of the BMI in different...

ea0090p296 | Adrenal and Cardiovascular Endocrinology | ECE2023

Cardiometabolic and Kidney Biomarker Effects of Gender-affirming Hormone Therapy in Transgender Males

Filipa Araujo Barbara , Lopes Sofia , Ferreira Mafalda , Ruas Luisa , Paiva Sandra , Paiva Isabel

Introduction: Testosterone-based gender-affirming hormone therapy (GAHT) may have negative consequences on cardiovascular risk, with reported increased blood pressure, decreased HDL-cholesterol, and weight gain. Still, data on cardiometabolic changes in transgender men on GAHT remain controversial. Testosterone-based GAHT also modifies body composition and lean muscle mass, but the degree to which affects serum creatinine and other measures of kidney function is still not clea...

ea0090p174 | Reproductive and Developmental Endocrinology | ECE2023

Congenital Adrenal Hyperplasia – When does Gender Identity Begin?

Lopes Sofia , Ferreira Mafalda , Araujo Barbara , Ruas Luisa , Paiva Sandra , Oliveira Patricia , Paiva Isabel

Introduction: Congenital adrenal hyperplasia (CAH) is a genetic condition which impairs enzymatic steroidogenesis of the adrenal cortex, leading to excessive androgen production. CAH phenotype is heterogeneous. In the mildest forms, it can present with hirsutism, acne and menstrual irregularities. Problems related to gender identification arise in about 5% of people with CAH with a 46,XX karyotype.Objective: We present the case of a young female-to-male ...

ea0090ep187 | Calcium and Bone | ECE2023

Hyperparathyroidism Jaw Tumour Syndrome in Pregnancy: A rare coexistence

Lopes Sofia , Monsanto Alice , Ferreira Mafalda , Ventura Mara , Ruas Luisa , Oliveira Patricia , Paiva Isabel

Introduction: Only <1% of cases of primary hyperparathyroidism (PHPT) occur during pregnancy. PHPT increases risk of complications such as miscarriage, premature birth and life-threatening maternal hypercalcemic crises. Hyperparathyroidism Jaw Tumor Syndrome (HPT-JT) is a rare inherited cause of PHPT, resulting from CDC73 gene mutations. There are a few reports described about HPT-JT in pregnancy. Although parathyroidectomy is the definite treatment for PHPT, given the sca...

ea0063p1195 | Thyroid 3 | ECE2019

Amiodarone-induced thyrotoxicosis: when combined treatment is an option

Silva Diana , Ruas Luisa , Cunha Nelson , Catarino Diana , Fadiga Lucia , Guiomar Joana , Carrilho Francisco

Introduction: Amiodarone is an effective drug in the management of supraventricular arrhythmias. Due to its composition rich in iodine and pharmacological properties can cause thyroid dysfunction in 15–20% of the treated patients. Clinically it can present in the form of amiodarone-induced hypothyroidism or amiodarone-induced thyrotoxicosis. This latter situation may result from an excess of iodine supply, glandular destruction or both pathogenic mechanisms.<p class="...

ea0026p302 | Obesity | ECE2011

Obesity in GDM

Ruas Luisa , Alves Marcia , Paiva Sandra , Marta Elvira , Lobo Antonio , Moura Paulo , Carvalheiro Manuela

Introduction: Retrospective study, 2003–07, of 619 GDM women.Patients and methods: Two groups according to pre-pregnancy BMI: Go ≥30, Gno <30 kg/m2. Influence of BMI in: family history of DM, previous GDM or macrossomia, gestational age at time of GDM diagnosis, weight gain, blood pressure, A1c, need and doses of Insulin, time and type of delivery, new- born weight, complications and re-evaluation post partum.<p class="abste...

ea0016p220 | Diabetes and cardiovascular diseases | ECE2008

GDM in women younger and older than 28 years: are there any differences in phenotype and biochemical markers?

Paiva Sandra , Ruas Luisa , Santos Jacinta , Marta Elvira , Sobral Ermelinda , Lobo Antonio , Carvalheiro Manuela , Moura Paulo

Goal: The aim of this study was to find different characteristics between GDM women aged under (GDM A n=23) and above 28 years (GDM B n=107), followed in our department in 2005.Material and methods: We performed ANOVA comparisons and computed Pearson correlations/linear regressions between womens’ age and BMI, O’ Sullivan test, OGTT 0 h, 1 h, 2 h and 3 h, new born weight and the need of insulin.Results: BMI ...

ea0035p296 | Clinical case reports Thyroid/Others | ECE2014

Type 2 polyglandular autoimmune syndrome and Turner syndrome

Moreno Carolina , Rodrigues Dircea , Vieira Alexandra , Ruas Luisa , Saraiva Joana , Guelho Daniela , Cardoso Luis , Vicente Nuno , Carrilho Francisco

Introduction: Individuals with Turner syndrome (TS) are prone to develop autoimmune conditions. The most frequently found are Hashimoto’s thyroiditis, type 1 diabetes, coeliac disease, and inflammatory bowel disease. In patients with TS, Addison’s disease isolated or combined with other autoimmune disease as type 2 polyglandular autoimmune syndrome, is a rare finding.Case report: We report a case of a 41-year-old female patient, with severe ast...

ea0035p1008 | Thyroid (non-cancer) | ECE2014

Recurrence of Graves' disease after radioiodine treatment: factors related to treatment failure

Moreno Carolina , Pires Luis , Cardoso Luis , Ruas Luisa , Saraiva Joana , Guelho Daniela , Vicente Nuno , Costa Gracinda , Carrilho Francisco

Introduction: Radioiodine (RAI) therapy is an inexpensive and reliable therapeutic option for Graves’ disease (GD). However, individual characteristics of the disease can influence therapeutic success. The identification of these factors may help to predict outcome and select optimal pre-treatment conditions.Aim: To assess clinical, laboratory and radioactive parameters that may lead to RAI treatment failure in patients with GD....

ea0035p1009 | Thyroid (non-cancer) | ECE2014

Severe side effects of methimazole in the treatment of hyperthyroidism

Moreno Carolina , Alves Marcia , Paiva Isabel , Rodrigues Dircea , Ruas Luisa , Saraiva Joana , Guelho Daniela , Vicente Nuno , Cardoso Luis , Carrilho Francisco

Introduction: Methimazole is the thionamide compound most used in the treatment of hyperthyroidism due to its efficacy, commodity and security. Severe side effects are rare, although potentially fatal: agranulocytosis in 0.1–0.5% and toxic hepatitis in 0.1%Aims: To characterize the patients admitted in the endocrinology ward for the last 10 years for severe complications of methimazole therapy.Material and Methods: Retrospecti...